Literature DB >> 21145581

Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study.

Mercedes C Becerra1, Sasha C Appleton, Molly F Franke, Katiuska Chalco, Fernando Arteaga, Jaime Bayona, Megan Murray, Sidney S Atwood, Carole D Mitnick.   

Abstract

BACKGROUND: Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis have emerged as major global health threats. WHO recommends contact investigation in close contacts of patients with MDR and XDR tuberculosis. We aimed to assess the burden of tuberculosis disease in household contacts of such patients.
METHODS: We undertook a retrospective cohort study of household contacts of patients treated for MDR or XDR tuberculosis in Lima, Peru, in 1996-2003. The primary outcome was active tuberculosis in household contacts at the time the index patient began MDR tuberculosis treatment and during the 4-year follow-up. We examined whether the occurrence of active tuberculosis in the household contacts differed by resistance pattern of the index patient: either MDR or XDR tuberculosis.
FINDINGS: 693 households of index patients with MDR tuberculosis were enrolled in the study. In 48 households, the Mycobacterium tuberculosis isolate from the index patient was XDR. Of the 4503 household contacts, 117 (2·60%) had active tuberculosis at the time the index patient began MDR tuberculosis treatment-there was no difference in prevalence between XDR and MDR tuberculosis households. During the 4-year follow-up, 242 contacts developed active tuberculosis-the frequency of active tuberculosis was nearly two times higher in contacts of patients with XDR tuberculosis than it was in contacts of patients with MDR tuberculosis (hazard ratio 1·88, 95% CI 1·10-3·21). In the 359 contacts with active tuberculosis, 142 (40%) had had isolates tested for resistance against first-line drugs, of whom 129 (90·9%, 95% CI 85·0-94·6) had MDR tuberculosis.
INTERPRETATION: In view of the high risk of disease recorded in household contacts of patients with MDR or XDR tuberculosis, tuberculosis programmes should implement systematic household contact investigations for all patients identified as having MDR or XDR tuberculosis. If shown to have active tuberculosis, these household contacts should be suspected as having MDR tuberculosis until proven otherwise. FUNDING: The Charles H Hood Foundation, the David Rockefeller Center for Latin American Studies at Harvard University, and the Bill & Melinda Gates Foundation. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21145581     DOI: 10.1016/S0140-6736(10)61972-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  57 in total

1.  Concordance of resistance profiles in households of patients with multidrug-resistant tuberculosis.

Authors:  Jonathan B Parr; Carole D Mitnick; Sidney S Atwood; Katiuska Chalco; Jaime Bayona; Mercedes C Becerra
Journal:  Clin Infect Dis       Date:  2013-10-28       Impact factor: 9.079

2.  Spatial Patterns of Extensively Drug-Resistant Tuberculosis Transmission in KwaZulu-Natal, South Africa.

Authors:  Kristin N Nelson; N Sarita Shah; Barun Mathema; Nazir Ismail; James C M Brust; Tyler S Brown; Sara C Auld; Shaheed Vally Omar; Natashia Morris; Angie Campbell; Salim Allana; Pravi Moodley; Koleka Mlisana; Neel R Gandhi
Journal:  J Infect Dis       Date:  2018-11-05       Impact factor: 5.226

3.  Extensively drug-resistant tuberculosis in South Africa: genomic evidence supporting transmission in communities.

Authors:  Sara C Auld; N Sarita Shah; Barun Mathema; Tyler S Brown; Nazir Ismail; Shaheed Vally Omar; James C M Brust; Kristin N Nelson; Salim Allana; Angela Campbell; Koleka Mlisana; Pravi Moodley; Neel R Gandhi
Journal:  Eur Respir J       Date:  2018-10-18       Impact factor: 16.671

4.  Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease.

Authors:  Amita Gupta; Susan Swindells; Soyeon Kim; Michael D Hughes; Linda Naini; Xingye Wu; Rodney Dawson; Vidya Mave; Jorge Sanchez; Alberto Mendoza; Pedro Gonzales; Nagalingeswaran Kumarasamy; Kyla Comins; Francesca Conradie; Justin Shenje; Sandy Nerette Fontain; Anthony Garcia-Prats; Aida Asmelash; Supalert Nedsuwan; Lerato Mohapi; Umesh G Lalloo; Ana Cristina Garcia Ferreira; Christopher Mugah; Mark Harrington; Lynne Jones; Samyra R Cox; Betsy Smith; N Sarita Shah; Anneke C Hesseling; Gavin Churchyard
Journal:  Clin Infect Dis       Date:  2020-01-16       Impact factor: 9.079

5.  Drug-resistant tuberculosis: what are the treatment options?

Authors:  Amr S Albanna; Dick Menzies
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

6.  Transmission of Extensively Drug-Resistant Tuberculosis in South Africa.

Authors:  N Sarita Shah; Sara C Auld; James C M Brust; Barun Mathema; Nazir Ismail; Pravi Moodley; Koleka Mlisana; Salim Allana; Angela Campbell; Thuli Mthiyane; Natashia Morris; Primrose Mpangase; Hermina van der Meulen; Shaheed V Omar; Tyler S Brown; Apurva Narechania; Elena Shaskina; Thandi Kapwata; Barry Kreiswirth; Neel R Gandhi
Journal:  N Engl J Med       Date:  2017-01-19       Impact factor: 91.245

7.  Clinical outcomes among persons with pulmonary tuberculosis caused by Mycobacterium tuberculosis isolates with phenotypic heterogeneity in results of drug-susceptibility tests.

Authors:  Nicola M Zetola; Chawangwa Modongo; Patrick K Moonan; Ronald Ncube; Keikantse Matlhagela; Enoch Sepako; Ronald G Collman; Gregory P Bisson
Journal:  J Infect Dis       Date:  2014-01-16       Impact factor: 5.226

8.  Designing of phenol-based β-carbonic anhydrase1 inhibitors through QSAR, molecular docking, and MD simulation approach.

Authors:  Shahzaib Ahamad; Md Imtaiyaz Hassan; Neeraja Dwivedi
Journal:  3 Biotech       Date:  2018-05-14       Impact factor: 2.406

9.  How many sputum culture results do we need to monitor multidrug-resistant-tuberculosis (MDR-TB) patients during treatment?

Authors:  Saskia Janssen; Xavier Padanilam; Rianna Louw; Russel Mahanyele; Gerrit Coetzee; Thomas Hänscheid; Tjalling Leenstra; Martin P Grobusch
Journal:  J Clin Microbiol       Date:  2012-12-05       Impact factor: 5.948

Review 10.  Newer Drugs for Tuberculosis Prevention and Treatment in Children.

Authors:  Ben J Marais
Journal:  Indian J Pediatr       Date:  2019-02-01       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.